When I was an aspiring (much younger) scientist, one of the challenges was finding quality antibodies to accommodate our research group’s high-throughput Western blotting platform ¹ while studying signaling pathways in cancer cell lines. When I got into marketing, I learned about ABclonal’s high-quality, high-specificity, and high-affinity antibody products. I really wish that I had access to these products when I was doing my thesis research! With a team of passionate, capable scientists supporting these quality products, I was thrilled at the opportunity to be part of this company and to help spread ABclonal’s brand to the scientific community.

The cell cycle is a series of phases that takes place in a cell as it grows and divides. The cell spends most of its time in interphase. During this interphase the cell grows, replicates its chromosomes, and prepares for cell division. Once the cell leaves interphase, it will undergo the process of mitoses and start divining in order to create daughter cells. These new daughter cells will then enter their own interphase and begin a new round of the cell cycle. The cell cycle and its cues are of the utmost importance, because without the cues the cells can either multiply continuously, forming masses, or will not multiply. These cues are cyclins which controls the cell cycle progression.

The tumor is an abnormal tissue mass formed when cells divide and grow excessively within the body. Tumors can be benign (not cancerous) or malignant (cancerous). Benign tumors may become larger but do not spread to nearby tissue or other parts of the body. Malignant tumors, on the other hand, can spread nearby to tissue and can also be transmitted to other parts of the body through the blood and or lymphatic system.1 But we are no strangers to tumors and how the develop.

On the other hand, many of us aren’t as familiar with a tumor’s environment. Tumor progression is profoundly affected by the subtle interaction of tumor cells with immune and non-immune cells within their environment. In particular, the interactions with the immune cell component of a tumor are fundamental in determining whether primary tumors are eradicated, metastasized, or established by dormant micro metastases.3 The environment that a tumor grows in is also much more complex than one would think because of its highly variable cell composition, large number of proteins, and structures involved in tumor formation.

This being said, tumor microenvironment includes:
• Heterogeneous populations of cancer cells
• A variety of resident and osmotic host cells
• Secretion factors
• Extracellular matrix proteins

Cell proliferation assays have a wide range of applications in scientific research – from testing drug reagents to the effect of growth factors, from testing cytotoxicity to analyzing cell activity. So, what are cell proliferation assays? Cell proliferation assays typically detect changes in the number of cells in a division or changes in a cell population.

In some ways, the heart is quite a vulnerable organ. Cardiac complications such as heart attack, cardiac arrest, or heart failure are common. But interestingly, of the many diseases that may affect the heart, cancer is not one of them. For example, we often hear about cancer in the prostate, breast, colon, skin, etc., but rarely of the heart. How is this vital organ different?

The Problem with Cancer Models

Very few cancer drugs succeed in clinical trials, despite showing promise in the lab. Treatments that may work on animal models, cell lines, or even patient-derived xenografts often do not have the same efficacy in patients. The underlying reason is tumor environments within the human body are far more complex than in research models. For example, the tissue structure (histological complexity) and genetic heterogeneity of an animal model is different than that of humans. Even cell lines and patient-derived xenografts, which are human-derived, have their own pitfalls such as genetic mutations and animal-specific tumor evolution, respectively. Due to the inability to reproduce human tumor environments, many drugs fail clinical trials after lengthy and costly development.